DOCSLIB.ORG

A Window to the Israeli Pharma and Biotech Industries Workshop Agenda January 13-17,2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Window to the Israeli Pharma and Biotech Industries Workshop Agenda January 13-17,2019 A Window to the Israeli Pharma and Biotech Industries Workshop Agenda January 13-17,2019 סדנת "חשיפה לתעשיית הפארמה והביוטק בישראל" מאורגנת זו השנה השנייה על ידי ScienceAbroad בחסות חברת טבע ובשיתוף פעולה עם המרכז לקליטה במדע והאגף ליזמות עסקית במשרד העליה והקליטה. הסדנא כוללת שלושה ימי עיון בהם הרצאות בכירים, פאנלים של מדענים חוזרים, משאבי אנוש, מגייסים וממשל, יום סיור בתעשייה (טבע, VBL), יום יזמות וחדשנות בחממת סנארה ואירוע נטוורקינג בחסות משותפת של קרן aMoon ורשת 8400 בהשתתפות בכירים מהמשק הישראלי ומשקיעים. מטרות כלליות 1. לעודד חזרתם של מדענים ישראלים השוהים בחו"ל לתפקידים שונים בתעשייה ולהזדמנויות בתחום היזמות בישראל. 2. להציג את התעשייה הישראלית ואת ההזדמנויות הקיימות עבור מדענים יעדים 1. להציג למדענים את המגמות בתחומי מחקר ופתוח בתעשייה בישראל 2. לחשוף בפני המדענים הזדמנויות מקצועיות ותעסוקתיות בתעשייה הישראלית ולייצר להם קשרים עם מעסיקים פוטנציאליים 3. לספק כלים למעבר ממחקר אקדמי למחקר יישומי בתעשייה 4. להכיר את תחום היזמות ואת כלי הסיוע והתמריצים שמספקת מדינת ישראל על ScienceAbroad ארגון המדענים הישראלים בחו"ל ScienceAbroad הוא ארגון ללא כוונות רווח הפועל מאז 2006, לשמירת קשר עם חוקרים ישראלים בעולם והשבת המוחות לישראל. ScienceAbroad הוא קהילה בינלאומית עבור יותר מ- 2800 חוקרים ישראלים ב300 קמפוסים ברחבי העולם. הארגון מפעיל 23 מרכזים בארה"ב, קנדה ואנגליה המנוהלים על ידי מדענים מתנדבים. הארגון מעניק כלים, מפתח קשרים ופותח דלתות למדענים ישראלים המבקשים לשוב לישראל על מנת שיביאו עימם את הידע, הכישרון, הניסיון והקשרים שצברו לאקדמיה ולתעשייה כמנוע צמיחה לישראל. משתתפים ושותפים יקרים, אנו מבקשים לברך אתכם על ההחלטה לקחת חלק בסדנת "חשיפה לתעשיית הפארמה והביוטק בישראל" המאורגנת זו השנה השנייה על ידי ScienceAbroad בחסות חברת טבע ובשיתוף פעולה עם המרכז לקליטה במדע והאגף ליזמות עסקית במשרד העליה והקליטה. הבחירה שלכם היא לרב צעד אמיץ לקראת שינוי נתיב קריירה וחשיפה להזדמנויות חדשות ופחות מוכרות. סיינס אברוד פועל מזה 12 שנה לשמירת קשר עם ישראלים בעלי תארים מתקדמים ברחבי העולם והשבת המוחות לישראל. חזוננו הוא שישראל תהא אבן שואבת לחוקרים מכל העולם ואנו מאמינים כי מינוף ומיצוב המו"פ בתעשייה בישראל לצד ניתוב מדענים למסלולי תעשייה ויזמות יכולים להביא להגשמת החזון. מנתונים מעודכנים לשנת 2017 עולה כי 11% מכלל המסיימים לימודי דוקטורט במוסדות להשכלה גבוהה בישראל, מתגוררים בחו"ל במשך למעלה משלוש שנים! עזיבת מדענים את ישראל גוררת השלכות למשק הישראלי בדמות הפסד הכנסות עתידיות מן התושבים שעזבו. בסקרים שקיימנו בשנה האחרונה מצאנו כי החסם העיקרי לחזרה לישראל הוא התעסוקה. מחד מיעוט של משרות באקדמיה ומאידך קושי להשתלב במו"פ בתעשייה בישראל בגלל חוסר ניסיון תעסוקתי בתעשייה והיצע משרות נמוך. רק 7% מבוגרי דוקטורט במדעי החיים מצליחים למצוא עבודה באקדמיה, אף שזו לרוב כוונתם. עוד 9% משתלבים בתעשיית הביוטק, כולל האגרו-טק (חדשנות בחקלאות). במערכת הבריאות (לרוב כעובדי ומנהלי מעבדות) משתלבים עוד כ14.5%-. כלומר, רק כ30%- עובדים ממש במקצוע. ( ד"ר נורית איל, מתוך מחקר של התוכנית להשבת אקדמאים) כדי להקים בישראל תעשיית מדעי חיים משגשגת שתהא אבן שואבת לאנשי מחקר ופיתוח נדרשים הון אנושי והון. וכאן אנחנו פוגשים אתכם – אתם ההון האנושי, אתם מנוע הצמיחה של ישראל! אנו מקווים שהתכנית תאפשר לכם הרחבה של הידע וההיכרות עם תעשיית מדעי החיים בישראל ובעיקר תאפשר לכם יצירת קשרים שיסייעו לכם בהשתלבות תעסוקתית בישראל. מאחלים לכם סדנא מוצלחת, נשמח לראות אתכם משתלבים בעוד תכניות של הארגון. מוניקה לב כהן, ד"ר שמוליק הס, יו"ר מנכ"לית ScienceAbroad מייסד ושותף ScienceAbroad מדענים ישראלים יקרים, ברוכים הבאים הביתה לישראל. אנו נרגשים לתת חסות לסדנת ה"חשיפה לתעשיית הפארמה והביוטק בישראל." לאורך 117 שנות קיומה צמחה חברת טבע לצידה של תעשייה מדעית ישראלית חזקה ומתקדמת. מאז ועד היום, ההון האנושי הישראלי מהווה את אחד המפתחות המשמעותיים ביותר להצלחתה וצמיחתה של תעשיית ביו-פארמה תחרותית וברת-קיימא בישראל . אנו רואים חשיבות עצומה בהשבת "מוחות ישראלים", כמוך. הכישרון, הניסיון אותו אתם מביאים והחשיפה למעבדות המחקר המובילות בעולם, יאפשרו לתעשיית הביו-פארמה הישראלית להמשיך להתפתח ולעמוד בחזית המדע. לחברת טבע יש שני מרכזי מו"פ מהגדולים בארץ, בנתניה ובכפר-סבא, המתמחים בפיתוח תרופות אינובטיביות וגנריות – כימיות וביולוגיות כאחד ונשמח לראותך משתלבים בעתיד. אנו רוצים להודות לארגון "סיינסאברוד" על היוזמה והשותפות בקיום הסדנה השבוע. בהצלחה לכולנו, איריס בק קודנר סמנכ"לית בכירה, חברת הנהלת טבע A Window to the Israeli Pharma and Biotech Industries Workshop Agenda January 13-17,2019 Day 1 – Introduction and Preclinical Development (Tel Aviv) Opening Remarks Dr. Shmuel Hess – Chairman, ScienceAbroad Ms. Iris Beck-Codner - Executive Vice President, Global Brand & Communications ,Teva Pharmaceuticals 09:00-09:45 Ms. Granit Ben Ezra Zinger - Director of the Center for Absorption in Science, MoAI Ms. Irus Huminer, - Director of the Department of Business Entrepreneurship, MoAI Mr. Yossi Weinstock - Partner at Pearl Cohen Zedek Latzer Baratz Introduction to Drug Development 09:45-10:30 Dr. Elijahu Berkovich - Clexio Biosciences 10:30-10:45 Coffee Break Drug Discovery in Industry Setting 10:45-11:30 Dr. Yael Marantz - VP Nonclinical Development, Head of ABIC site in IL, Teva Pharmaceuticals Introduction to Biosimilar Drugs Development 11:30-12:15 Dr. Nir Shapir - VP Biologics, CMC Biosimilars, Teva Pharmaceuticals 12:15-13:00 Lunch Clinical Pharmacology 13:00-13:45 Dr. Ofer Spiegelstein - VP, Innovation Initiatives, Specialty R&D, Teva Pharmaceuticals Introduction to CMC 13:45-14:30 Dr. Daniella Gutman - VP, Generic R&D, and site head Israel & Hungary, Teva Pharmaceuticals 14:30-14:45 Break Preclinical Pharmacology 14:45-15:30 Dr. Aric Orbach – DVM, Senior Director, Head of Pharmacology, Teva Pharmaceuticals Toxicology and ADME 15:30-16:15 Dr. Hilla Kedar - Senior Director, Head of Nonclinical Safety, Teva Pharmaceuticals Day 2 – Clinical Development (Tel Aviv) Introducing Teva 09:00-09:45 Mr. Mati Gill - Head of Government Affairs, Corporate & International Markets, Teva Pharmaceuticals Ms. Eti Raihenshtein – Director, Talent Acquisition International Market, Teva Pharmaceuticals Planning of a Clinical Trial 09:45-10:30 Dr. Eran Harary, - Senior Director, Global Clinical Development, Neuropsychiatry, Teva Pharmaceuticals 10:30-10:45 Coffee Break Operational Aspects of Clinical Trials 10:45-11:30 Ms. Shoshi Friedman, B.S.N R.N - VP Global Clinical Operations, Teva Pharmaceuticals Drug Manufacturing to Support a Clinical Study 11:30-12:15 Dr. Tal Hasson - Associate Director, Analytical Development, Specialty CMC, Teva Pharmaceuticals 12:15-13:00 Lunch Regulatory Affairs 13:00-13:45 Ms. Levana Volovsky - Director, Global Regulatory Affairs, CNS, Teva Pharmaceuticals Legal Aspects in Drug Development and Tech Transfer 13:45-14:30 Ms. Efrat Shalom-Berensohn, LL.M - Senior Director, General Counsel, Global R&D, Teva Pharmaceuticals 14:30-14:45 Break Returning Scientists Panel Moderator: Dr. Ianai Fishbein – Associate Director, Nonclinical Development, Teva Pharmaceuticals Dr. Moshe Ben-David – R&D Director, Ukko 15:30-16:30 Dr. Reut Shema – Associate, aMoon Fund Dr. Arik Zur - Associate Director of Clinical Pharmacology, BioLineRx Dr. Moran Grossman – Senior Scientist at MabTrix Dr. Irit Carmi-Levy - Project Director at BioLineRx Day 3 – Cross Functional Work (Tel Aviv) 09:00-09:45 Cell Therapy – Therapy of the Future: Opportunities and Challenges Mr. Nadav Eshkol - Technology and Process Development Manager, Pluristem Therapeutics Translational Medicine, 09:45-10:30 Dr. Jennifer Dreymann - Director, Translational Medicine Expert, Teva Pharmaceuticals 10:30-10:45 Coffee Break Pharmacovigilance 10:45-11:30 Ms. Orit Stern-Maman - VP Global Patient Safety & Pharmacovigilance, Teva Pharmaceuticals Business Development 11:30-12:15 Mr. Itamar Yaron - Senior Director, M&A and Global Alliances, Business Development & Strategy, Teva Pharmaceuticals 12:15-13:00 Lunch Commercialization 13:00-13:45 Mr. Avinoam Sapir – SVP, Cluster Manager – Teva Israel, Turkey, Ukraine & Africa, Teva Pharmaceuticals Personalized Medicine and Digital Health 13:45-14:30 Dr. Daphna Laifenfeld - Chief Strategy Officer at Ibex Medical Analytics 14:30-14:45 Break The Israeli Life Science Industry – Trends and Opportunities 14:45-15:30 Dr. Itai Kela - Senior Director - Head of Healthcare and Biotechnology sectors at Israel Innovation Authority HR Panel Moderator: Ms. Lizi Shoov London – Partner & Managing Director, Nisha Group Ms. Liat Duani - Senior Consultant, Diva Keren Creative HR 15:30-17:00 Ms. Cohav Nir - Senior Manager, Sourcing & Employer Branding, Teva Pharmaceuticals Ms. Limor Lior - Organization Development Manager & HRP, Pluristem Therapeutics Mr. Jonathan Solomon - CEO at BiomX Ltd. Day 4 – Innovation and Startups (Ra’anana) Introduction to the Innovation and Startup World 09:00-10:15 Mr. Assaf Barnea – CEO Sanara Ventures Governmental and NGO’s Assistance Session Ministry of Aliya and Integration – Business Entrepreneurship Dept Ms. Irus Huminer – Director of the Department of Business Entrepreneuship, MoAI 10:15-11:30 IATI Ms. Karin Mayer Rubinstein - CEO and President, IATI The Health Network-8400 Ms. Daphna Murvitz – Co-founder and CEO, 8400 11:30-11:45 Coffee Break Failure and Success Factors of Technological Startup Companies – 11:45-12:30 Lessons from Personal Experience Mr. Zohar Gendler - CEO & Managing Partner, NGT3 Introduction to Digital Health 12:30-13:15 Mr. Ophir Shahaf - VP Business Development at eHealth Ventures Incubator 13:15-13:55 Lunch Venture Capital Funds Panel Moderator: Dr. Neta Kela-Madar – Head of Innovation and Entrepreneurship Center, SCE Dr. Yuval Cabilly – Founder and Managing Partner, Israel Biotech Fund 13:55-15:30 Dr. Pini Orbach - Head of Pharma at Arkin Holdings Dr. Dov Tamarkin - CEO at Tamarkin Ventures Dr. Omri Amirav-Drory - Founding Partner at tech.bio 15:30-15:45 Break Startup Panel Moderator: Dr. Shmuel Hess - CEO, Enlivex Therapeutics Dr. Amir Bahar - Co-Founder COO & Clinical Dir. Nurami Medical 15:45-17:30 Mr. Yoav Grinstein – COO, Our Clinical Trial Dr. Eyal Fima – Entrepreneur, Advisor Dr. Roni Mamluk – CEO, Ayala Pharmaceuticals Networking Event – co-hosted by aMoon and 8400 18:00 aMoon offices, Ra’anana Day 5 – Tours 10:00-13:00 Tour at Teva Pharmaceuticals, Kfar Saba 14:00-17:00 Tour at VBL Therapeutics, Modi’in *Schedule may be subject to change. Important Note Attendance at this event is mandatory, in particular for the attendees who have received funding for their travel.
Load more

Recommended publications
  • Strauss Group Sustainability Report 2020
    Strauss Group Sustainability Report 2020 GRI Content Index 1 STRAUSS GROUP 2020 SUSTAINABILITY REPORT - GRI CONTENT INDEX This is Strauss Group’s 13th sustainability report. It describes the impact of the Group’s business, social and environmental activities on its stakeholders in 2020. This report was prepared in accordance with standards of the Global Reporting Initiative (GRI): Core Option. Furthermore, the report represents the Group’s annual report to the Global Compact project of the United Nations, which it has been a member of since 2008. The information in the report refers to the 2020 calendar year. Our previous full sustainability report was published in 2020 and referred to 2019. We intend to continue to publish our sustainability report on an annual basis. In this report, we kept to the same essential framework from 2014. Based on strategic work that was carried out in 2019 and on internal verification, we found that this framework is still relevant today. The parameters of this report are unchanged – the report deals with all the companies in Strauss Group that are under our operational control, including joint ventures that are reported as full entities. No substantial retroactive amendments were made to data that was presented in previous reports. Minor adjustments that were made are indicated alongside the data as they are shown. This summary, as well as the 2020 Sustainability Report are not part of Strauss Group’s financial, immediate or periodic statements. In the event of a discrepancy between what is stated in this report and the aforementioned reports, the wording of the financial statements is the binding one.
    [Show full text]
  • Advancing Cell Therapeutic Products for Clinical Use
    Advancing cell therapeutic products for clinical use 1 Proprietary data of Pluristem Therapeutics Inc. Forward Looking Statement This presentation concerning Pluristem Therapeutics may include forward- looking statements which represent Pluristem Therapeutics' expectations or beliefs regarding future events. I caution that such statements involve risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Consequently, all such forward-looking statements are qualified by the cautionary language and risk factors set forth in Pluristem Therapeutics' periodic and other reports filed with the SEC. There can be no assurance that the actual results, events or developments referenced in such forward-looking statements will occur or be realized. Pluristem Therapeutics assumes no obligation to update these forward- looking statements to reflect actual results, changes in assumptions or changes in factors affecting such forward-looking statements. www.pluristem.com 2 Proprietary data of Pluristem Therapeutics Inc. Corporate Overview • Cell therapy company (NasdaqCM: PSTI, TASE: PSTI) • Using off-the-shelf, placenta-derived cells to achieve both local and systemic therapeutic effects – no tissue matching needed • First-in-class 3D cell culturing technology allowing for efficient, controlled production of multiple cell products in commercial quantities – “the process is the product” • Active with regulators in the U.S., EU, S. Korea, Australia & Israel • Demonstrated safety and efficacy in 3 clinical studies (two Phase I and one Phase I/II study) 3 Proprietary data of Pluristem Therapeutics Inc. Financial Overview • Market Cap: ~ $200 million • Cash and marketable securities: $41 million (March, 2015) • No debt • Net burn: ~ $23 million • 165 employees (16 PhD, 4 MD) • IP Ownership: over 40 granted patents and ~150 pending applications 4 Proprietary data of Pluristem Therapeutics Inc.
    [Show full text]
  • Bluestar Israel Quarterly Update Q3 2013 Final.Pptx
    BlueStar Israel Equity Update Third Quarter 2013 Q2 2013 in Review & Second Half 2013 Outlook What’s Inside Ø Global developed market equities pulled back slightly in Q2 2013 while U.S. stocks, as measured by the S&P 500 index, bucked the trend and posted a rise of 2.91%. Ø The BlueStar Israel Global Index was down by 95 bps in Q2 2013 while the MSCI Israel and TA-100 indexes were down 4.16% and 2.76%, respectively. 1. The BlueStar Ø Israeli consumer stocks, which are correlated with both domestic consumption as well as consumer spending in Israel’s export markets, lead Israeli Global Equities in Q2, while the Israel Global financial and energy stocks, which lead the Israeli Global Equity market’s rebound from the Index in Q1 2012 lows, consolidated. 2013 Ø The Israeli government decided on a 2013 and 2014 budget that will result in tax increases and spending cuts and the Shekel’s sharp appreciation versus the dollar and euro eased a bit. 2-5. About the Ø Mellanox Technologies announced it will delist its shares from the Tel Aviv Stock Exchange and the TASE’s bid to be included in MSCI’s European regional indexes was declined. Both BlueStar Israel events sparked concern about the future of the local exchange. Also, Israeli corporate Global Index pyramids come under attack by The Committee on Increasing Competitiveness in the Economy and the Business Concentration Law. (including Risk/ Ø The Energy sector is asserting itself as a major player in the Israeli economy, natural gas Return Data) reserve estimates and oil estimates are rising, and the government has decided upon an export strategy, clearing up uncertainty and removing some of the risk factors associated with investing in that sector.
    [Show full text]
  • Strauss Group United Nations Global Compact Communication on Progress 2017
    Strauss Group United Nations Global Compact Communication on Progress 2017 www.strauss-group.com Strauss Group – Communication on Progress 2017 2 Contents CEO Commitment .............................................................................................................. 3 About Strauss Group ........................................................................................................ 4 Our sustainability approach and strategy ....................................................................... 5 Advancing health and nutrition ........................................................................................ 7 Advancing the 10 Principles ............................................................................................. 8 Protecting human rights ........................................................................................................... 8 Upholding labor rights .............................................................................................................. 9 Environmental stewardship ................................................................................................... 10 Eliminating corruption ............................................................................................................ 10 About this Communication on Progress ....................................................................... 11 Strauss Group – Communication on Progress 2017 3 CEO Commitment On behalf of Strauss Group, I confirm our continuing participation in the UN Global
    [Show full text]
  • 2013 Catalyst Census and Include Information on 777 Board Members in Office in 2013
    The Strauss Group and the Israel Women's Network are proud to present: THE ISRAELI CATALYST REPORT WOMEN LEADING BUSINESS The Fourth Israeli Census Report 2013 Women's Representation in the TA-100 Companies Index MARCH 2014 DIVERSITY IS AN OPPORTUNITY Table of Contents Foreword 3 Executive summary 4 Part A: The 2013 Israel Catalyst Census Report 1. Main findings – the 2013 Israel Census 5 2. Introduction – What does the future hold? 8 3. Background, goals and methodology 9 4. Detailed findings – women on boards of directors 10 4.1 Women on boards of directors 10 4.2 Chairperson of the board positions held by women 11 4.3 Companies according to the number of women on the board of directors 11 4.4 Women on the board of directors by industry 12 4.5 International comparison – women on boards of directors 13 4.6 International comparison – companies with at least one woman on the board of directors 14 4.7 Summary – women on boards of directors 14 5. Detailed findings – women in top executive positions 15 5.1 Women in top executive positions 15 5.2 Chief Executive Officer positions held by women 15 5.3 Companies according to the number of women in top executive positions 16 5.4 Women in top executive positions by industry 17 5.5 Area of occupation in top executive positions - gender comparison 18 5.6 International comparison – women in top executive positions 18 6. Annexes 19 6.1 Census size 19 6.2 2012 Census data: Ranking of companies with 25% and more of women on the board of directors and in management 19 Part B: Accompanying research – how many women are "enough"? Adequate representation on the boards of directors of public companies 1.
    [Show full text]
  • Strauss-Group Ltd. Financial Statements 2011 ,31 As At
    STRAUSS-GROUP LTD. FINANCIAL STATEMENTS AS AT MARCH 31, 2011 WorldReginfo - b4e5ae69-61fe-4bb1-bb60-f4f58f0ac23f Board of directors Ofra Strauss, Chairperson Michael Strauss Dr. Michael Anghel Ronit Haimovitch Ran Madyan David Mosevics Dr. Arie Ovadia Meir Shanie Professor Dafna Schwartz Dalya Lev Akiva Moses President & CEO Gadi Lesin EVP, CLO & Company Michael Avner Secretary Auditor Somekh Chaikin KPMG Registered office Hasivim St. 49 P.O.B 194 Petach Tikva 49517, Israel WWW.STRAUSS-GROUP.CO WorldReginfo - b4e5ae69-61fe-4bb1-bb60-f4f58f0ac23f STRAUSS-GROUP LTD. TABLE OF CONTENS DESCRIPTION OF THE CORPORATION'S BUSINESS BOARD OF DIRECTORS' REPORT TO THE SHAREHOLDERS AS AT DECEMBER 31, 2010. FINANCIAL STATEMENTS AS AT DECEMBER 31, 2010. WorldReginfo - b4e5ae69-61fe-4bb1-bb60-f4f58f0ac23f TABLE OF CONTENS – Description of the Corporation's Business Part I – Description of the General Development of the Corporation's Business 1 Description of the General Development of the Corporation's Business 1 2 Segments of Activity 9 3 Investments in the Share Capital of the Corporation and Transactions in its Shares 11 4 Dividend Distribution 11 Part II – Other Information 5 Financial Information Relating to the Corporation's Areas of Business 12 6 General Environment and Impact of External Factors on the Corporation's Activity 17 Part III – Description of the Corporation's Business According to Segments of Activity 7 General – the Food and Beverage Industry 20 8 Synergies between the Group's Segments of Activity 22 9 The Israel Activity Framework
    [Show full text]
  • Biolinerx Ltd. (Translation of Registrant’S Name Into English) ______
    SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 _______________________ BioLineRx Ltd. (Translation of registrant’s name into English) _______________________ 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) _______________________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☑ Form 40-F ☐ Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: Yes ☐ No ☑ The registrant hereby announces that it has entered into an employment agreement with Hillit Mannor Shachar, M.D., MBA, M.S.F.S., to serve as its new Vice President Business Development, effective April 1, 2018. Dr. Shachar will be responsible for BioLineRx’s business development, commercialization of assets and pipeline strategy. Dr. Shachar joins BioLineRx with over 15 years of experience in senior business development, corporate development and venture capital positions in the life sciences field. Her recent experience has included service as Vice President Business Development of Pluristem Therapeutics (NASDAQ:PSTI), a leading developer of placenta-based cell therapy products, and Director of New Business Development at West Pharmacuetical Services. In addition, Dr. Shachar has served at several life science companies and venture capital funds, including Apax Partners, Nektar Therapeutics, Orex Computed Radiography, Kodak and Transpharma Medical.
    [Show full text]
  • PLURISTEM THERAPEUTICS INC. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 001-31392 PLURISTEM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 98-0351734 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) MATAM Advanced Technology Park, Building No. 5, Haifa, Israel 31905 (Address of principal executive offices) (Zip Code) Registrant's telephone number 011-972-74-7107259 Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common Stock, par value $0.00001 Nasdaq Capital Market Securities registered pursuant to Section 12(g) of the Act: None. (Title of class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • TUESDAY, MAY 24, 2016 07:30-17:00 Registration Open 09
    TUESDAY, MAY 24, 2016 07:30-17:00 Registration Open Welcome Ruti Alon, General Partner, Pitango Venture Capital, IATI Biomed Co- Chairperson 09:00 - 09:20 Dr. Benny Zeevi, Managing General Partner, Tel Aviv Venture Partners, IATI Biomed Co-Chairperson Yaky Yanay, President, Pluristem and IATI Co-Chairperson Opening Keynote Lecture: Patrick Terry, President, GMPO Orphan and Sharon Terry, President and 09:20-10:00 CEO of Genetic Alliance Interviewer: Francois Maisonrouge, Senior Managing Director, Evercore Partners Keynote Lecture: Francois Maisonrouge, Senior Managing Director, Evercore Partners - 10:00-10:40 ''The recent market correction in Health Care: a reflection of changing fundamentals?'' 10:40-11:10 Coffee Break Early Stage Challenges The Promise of Immuno- Neurological Disorders 11:10-17:30 and Opportunities Hall Oncology Hall A Hall B C 11:10-11:20: Jay D Kranzler, VP and Global Head, External 11:10-11:55: R&D Innovation – 11:10 - 11:20: Chairperson: Prof. Gal Biotherapeutics and Chairperson: Assaf Markel, MD, PhD, Sheba Strategic Investments, Barnea, CEO, Sanara Medical Center Pfizer, Inc. - ''CNS Ventures Therapeutics: From Starting Point to Tipping Point'' 11:55-12:40: Dr. Arie 11:20-12:00: Henry O Belldegrun, MD, Gosebruch, Executive Chairman, President & Vice President and 11:20 - 12:00: Jeroen Chief Executive Officer, Chief Strategy officer, Tas, CEO, Connected Kite Pharma - Abbvie - ''The Starting Care & Health "Engineered T cell Point: The CNS Informatics, Philips Immunotherapy: The Ecosystem as it Stands future is here" Today'' 12:00-12:40: Tetsuyuki Dr. Wei Siang Yu, Maruyama, Chief Medical Doctor, 12:40-13:25: TBA Scientific Officer, Medical Inventor, Dementia Discovery Healthcare ICT Fund - ''New Financing Entrepreneur and Vehicles: The Visionary, Founder of Dementia Discovery Borderless Healthcare Fund Example'' Group 12:00 - 13:30: Round Table Discussions: 1.
    [Show full text]
  • Life Sciences in Israel
    STATE OF ISRAEL Ministry of Industry Trade and Labor Investment Promotion Center Inspiration Invention Innovation Life Sciences in Israel www.investinisrael.gov.il Table of Contents .......................................... 3 Israel: A Powerhouse of Opportunities ............................................................ 3 Israel’s Life Science Sectors Medical Devices ........................................................................ 4 Healthcare IT ............................................................................ 4 BioPharmaceutical .................................................................... 7 Israel’s Biomedical Engineering - ................................................... 11 Spotlight on Stem Cell Research ....................................... 15 Israel’s Life Sciences Competitive Edge ..................................................................... 19 Government Support 2 Life Sciences in Israel Israel: A Powerhouse of Opportunities Why Israel’s Life Sciences Over the last decade, Israel has introduced a wealth of groundbreaking More than 1,000 Life and valuable innovations in Life Sciences. Israel’s Life Sciences sector Sciences Companies - is supported by a strong foundation of academic excellence, including Biopharma and Medical some of the world’s leading research institutes, renowned R&D Devices facilities and cutting-edge medical centers. Bolstered by a highly skilled Over 1/3 of LS Start-Ups workforce, a flourishing high-tech environment, and an entrepreneurial already generate revenue
    [Show full text]
  • Alphabetical Listing by Company Name
    FOREIGN COMPANIES REGISTERED AND REPORTING WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION December 31, 2015 Alphabetical Listing by Company Name COMPANY COUNTRY MARKET 21 Vianet Group Inc. Cayman Islands Global Market 37 Capital Inc. Canada OTC 500.com Ltd. Cayman Islands NYSE 51Job, Inc. Cayman Islands Global Market 58.com Inc. Cayman Islands NYSE ABB Ltd. Switzerland NYSE Abbey National Treasury Services plc United Kingdom NYSE - Debt Abengoa S.A. Spain Global Market Abengoa Yield Ltd. United Kingdom Global Market Acasti Pharma Inc. Canada Capital Market Acorn International, Inc. Cayman Islands NYSE Actions Semiconductor Co. Ltd. Cayman Islands Global Market Adaptimmune Ltd. United Kingdom Global Market Adecoagro S.A. Luxembourg NYSE Adira Energy Ltd. Canada OTC Advanced Accelerator Applications SA France Global Market Advanced Semiconductor Engineering, Inc. Taiwan NYSE Advantage Oil & Gas Ltd. Canada NYSE Advantest Corp. Japan NYSE Aegean Marine Petroleum Network Inc. Marshall Islands NYSE AEGON N.V. Netherlands NYSE AerCap Holdings N.V. Netherlands NYSE Aeterna Zentaris Inc. Canada Capital Market Affimed N.V. Netherlands Global Market Agave Silver Corp. Canada OTC Agnico Eagle Mines Ltd. Canada NYSE Agria Corp. Cayman Islands NYSE Agrium Inc. Canada NYSE AirMedia Group Inc. Cayman Islands Global Market Aixtron SE Germany Global Market Alamos Gold Inc. Canada NYSE Alcatel-Lucent France NYSE Alcobra Ltd. Israel Global Market Alexandra Capital Corp. Canada OTC Alexco Resource Corp. Canada NYSE MKT Algae Dynamics Corp. Canada OTC Algonquin Power & Utilities Corp. Canada OTC Alianza Minerals Ltd. Canada OTC Alibaba Group Holding Ltd. Cayman Islands NYSE Allot Communications Ltd. Israel Global Market Almaden Minerals Ltd.
    [Show full text]
  • Company Country
    Company Country 1 Teva Pharmaceutical ISR 2 Coca-Cola HBC AG GRC 3 Bank Hapoalim ISR 4 Israel Chemicals ISR 5 Bank Leumi ISR 6 Bezeq ISR 7 Azrieli Group ISR 8 Hellenic Telecommunications Organization S.A. GRC 9 Nice Systems ISR 10 Elbit Systems ISR 11 OPAP GRC 12 Mizrahi Tefahot Bank Ltd. ISR 13 Delek Group ISR 14 Frutarom ISR 15 Osem Investments ISR 16 Israel Discount Bank ISR 17 Israel Corporation ISR 18 Hellenic Petroleum S.A. GRC 19 Gazit Globe (1982) Ltd ISR 20 BANK OF CYPRUS PUBLIC COMPANY LTD CYP 21 Titan Cement Co. S.A. GRC 22 Melisron ISR 23 Alpha Bank S.A. GRC 24 National Bank of Greece S.A. GRC 25 Paz Oil ISR 26 Strauss Group ISR 27 Folli Follie GRC 28 Motor Oil Hellas Corinth Refineries S.A. GRC 29 First Intl Bank of Israel (5) ISR 30 Public Power Corp. S.A. GRC 31 Jumbo S.A. GRC 32 Oil Refineries ISR 33 Alony Hetz Properties & Inv ISR 34 Tower Semiconductor Ltd ISR 35 Migdal Insurance & Financial Holdings Ltd. ISR 36 Grivalia Properties R.E.I.C GRC 37 Harel Investments & Finance ISR 38 Delek Automotive Systems ISR 39 Amot Investments Ltd. ISR 40 Clal Insurance ISR 41 Delta Galil Industries ISR 42 Shikun & Binui Ltd ISR 43 Airport City Ltd ISR 44 Kenon Holdings ISR 45 Athens Water Supply & Sewerage GRC 46 Ezchip Semiconductor ISR 47 Jerusalem Oil Exploration ISR 48 Phoenix Holdings ISR Company Country 49 IDI Insurance Company Ltd ISR 50 Cellcom Israel Ltd. ISR 51 Partner Communications ISR 52 VIOHALCO SA/NV (CB) GRC 53 Mytilineos Holdings S.A.
    [Show full text]